SCHEMBL56844

SCHEMBL56844

C[C@@H](c1ccc(F)cc1)c1ccccn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 5/20 0.46
SLC6A2 P23975 5/20 0.46
SLC6A4 P31645 5/20 0.46
CHRM2 P08172 6/20 0.42
CHRM1 P11229 5/20 0.42
CHRM5 P08912 3/20 0.42
CHRM4 P08173 2/20 0.42
CHRM3 P20309 2/20 0.42
TSHR P16473 3/20 0.41
ALDH1A1 P00352 2/20 0.40
CYP3A4 P08684 2/20 0.40
LMNA P02545 2/20 0.40
CYP2C9 P11712 2/20 0.40
ADRA1A P35348 2/20 0.40
HIF1A Q16665 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ABCB11 O95342 1/20 0.40
ESR1 P03372 1/20 0.40
ADRA2A P08913 1/20 0.40
PDE4A P27815 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4150275 1.00 SLC6A3 (0.46) SLC6A3SLC6A2SLC6A4CHRM2CHRM1
SCHEMBL20385395 1.00 SLC6A3 (0.46) SLC6A3SLC6A2SLC6A4CHRM2CHRM1
SCHEMBL17069296 0.84 SLC6A2 (0.63) SLC6A3SLC6A2SLC6A4CHRM2CHRM1
SCHEMBL17069299 0.84 SLC6A2 (0.63) SLC6A3SLC6A2SLC6A4CHRM2CHRM1
SCHEMBL3103040 0.84 SLC6A2 (0.63) SLC6A3SLC6A2SLC6A4CHRM2CHRM1
SCHEMBL28985174 0.83 SLC6A3 (0.47) SLC6A3SLC6A2SLC6A4CHRM2CHRM1
SCHEMBL28985177 0.83 SLC6A3 (0.47) SLC6A3SLC6A2SLC6A4CHRM2CHRM1
Ammonia Solution, Strong SCHEMBL6267830 0.82 SLC6A2 (0.61) SLC6A3SLC6A2SLC6A4CHRM2CHRM1
SCHEMBL21911297 0.82 SLC6A3 (0.43) SLC6A3SLC6A2SLC6A4CHRM2CHRM1
SCHEMBL15470472 0.81 CHRM2 (0.55) SLC6A3SLC6A2SLC6A4CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122892-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2012-05-17 US disclosed
US-8129403-B2 e.g. 2-[9-(5-Cyclopropyl-1H-pyrazol-3-yl)-6-methyl-9H-purin-2-ylamino]-2-(4-fluorophenyl)ethanol; tropomyosin-related kinases (Trk's) inhibitor; anticarcinoganic agent; solid tumors and leukemia ASTRAZENECA AB (SE) 2012-03-06 US disclosed
US-20080176872-A1 Chemical Compounds ASTRAZENECA AB (SE) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176872-A1 Chemical Compounds TP53, XPOT, KRAS SLC6A3 4160/4885SLC6A2 4186/4885SLC6A4 4316/4885
US-20120122892-A1 CHEMICAL COMPOUNDS TP53, XPOT, KRAS SLC6A3 4000/4885SLC6A2 4017/4885SLC6A4 4164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.